文献速递湿疹皮炎与荨麻疹

度普利尤单抗在中重度特应性皮炎青少年和成人中实现早期持续瘙痒改善:四项随机3期研究分析

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
PubMed 文献 · J Am Acad Dermatol · 2020-03-03

本文分析4项随机对照研究共1505例中重度特应性皮炎患者,评估度普利尤单抗对瘙痒的作用。结果显示成人第2天、青少年第5天瘙痒评分即较基线显著改善,治疗结束时瘙痒改善幅度显著优于对照,且持续至治疗结束(最长52周)。

要点

  • 度普利尤单抗在成人第2天、青少年第5天即显著改善瘙痒。
  • 治疗结束时瘙痒评分较基线改善幅度显著优于对照。
  • 瘙痒改善随治疗持续增加并维持至治疗结束(最长52周)。

核心结论

  • 度普利尤单抗治疗在中重度特应性皮炎患者中实现快速且持续的瘙痒改善。

研究设计与样本

  • 分析4项随机对照研究(SOLO 1、SOLO 2、AD ADOL、CHRONOS)共1505例中重度特应性皮炎患者,治疗最长52周。
  • 成人接受度普利尤单抗300 mg每2周或安慰剂单药治疗(SOLO 1、SOLO 2),或联合外用糖皮质激素(CHRONOS)。
  • 青少年(≥12至<18岁)接受度普利尤单抗每2周单药治疗(基线体重<60 kg用200 mg,≥60 kg用300 mg)或安慰剂(AD ADOL)。

主要发现

  • 度普利尤单抗组每日峰值瘙痒数字评定量表评分较基线显著快速改善,成人第2天、青少年第5天即优于安慰剂。
  • 治疗结束时,度普利尤单抗组每周平均峰值瘙痒数字评定量表评分较基线的最小二乘均值百分比变化优于对照:SOLO -47.5% vs -20.5%;AD-ADOL -47.9% vs -19.0%;CHRONOS -57.3% vs -30.9%(所有P < .0001)。

关键数值与推荐

  • 成人第2天、青少年第5天瘙痒评分即显著改善。
  • SOLO研究治疗结束时瘙痒评分较基线变化:度普利尤单抗-47.5% vs 安慰剂-20.5%(P < .0001)。
  • AD-ADOL研究治疗结束时瘙痒评分较基线变化:度普利尤单抗-47.9% vs 安慰剂-19.0%(P < .0001)。
  • CHRONOS研究治疗结束时瘙痒评分较基线变化:度普利尤单抗-57.3% vs 对照-30.9%(P < .0001)。

临床怎么用

  • 度普利尤单抗可用于中重度特应性皮炎患者瘙痒的早期和持续控制。
  • 成人起效迅速,青少年起效稍晚但同样显著。
  • 联合外用糖皮质激素(CHRONOS)也显示瘙痒显著改善。

局限性

  • 单药治疗试验持续时间较短(16周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD). OBJECTIVE: To evaluate the timing and effect of dupilumab on itch. METHODS: Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1: NCT02277743; SOLO 2: NCT02277769), with concomitant topical corticosteroids (CHRONOS: NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL: NCT03054428). RESULTS: Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores: SOLO -47.5% vs -20.5%; AD-ADOL -47.9% vs -19.0%; CHRONOS -57.3% vs -30.9% (P < .0001 for all). LIMITATIONS: Short duration of monotherapy trials (16 weeks). CONCLUSION: Across 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020. PMID: 32135208. doi:10.1016/j.jaad.2020.02.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。